desoxycorticosterone acetate has been researched along with Obesity in 2 studies
Desoxycorticosterone Acetate: The 21-acetate derivative of desoxycorticosterone.
Obesity: A status with BODY WEIGHT that is grossly above the recommended standards, usually due to accumulation of excess FATS in the body. The standards may vary with age, sex, genetic or cultural background. In the BODY MASS INDEX, a BMI greater than 30.0 kg/m2 is considered obese, and a BMI greater than 40.0 kg/m2 is considered morbidly obese (MORBID OBESITY).
| Excerpt | Relevance | Reference |
|---|---|---|
| "Obesity and hypertension are prevalent comorbidities in heart failure with preserved ejection fraction." | 1.51 | Limited synergy of obesity and hypertension, prevalent risk factors in onset and progression of heart failure with preserved ejection fraction. ( Brandt, MM; Cheng, C; Cramer, MJ; Duncker, DJ; Joles, JA; Krebber, MM; Mokry, M; Nguyen, ITN; van de Wouw, J; Verhaar, MC, 2019) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 1 (50.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (50.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Brandt, MM | 1 |
| Nguyen, ITN | 1 |
| Krebber, MM | 1 |
| van de Wouw, J | 1 |
| Mokry, M | 1 |
| Cramer, MJ | 1 |
| Duncker, DJ | 1 |
| Verhaar, MC | 1 |
| Joles, JA | 1 |
| Cheng, C | 1 |
| OVERZIER, C | 1 |
2 other studies available for desoxycorticosterone acetate and Obesity
| Article | Year |
|---|---|
Limited synergy of obesity and hypertension, prevalent risk factors in onset and progression of heart failure with preserved ejection fraction.
Topics: Animals; Apoptosis; Capillaries; Desoxycorticosterone Acetate; Disease Progression; Fatty Acids; Fib | 2019 |
[Treatment of polyglandular disorders, especially paradoxical obesity, with desoxycorticosterone acetate].
Topics: Adrenal Cortex; Desoxycorticosterone Acetate; Metabolism; Obesity; Tissue Extracts | 1950 |